Architect of Valeant's Turnaround Is Under Fire

Michael Pearson, who reshaped Valeant Pharmaceuticals into a deal machine in seven-plus years as chief executive, is on the defensive as the drug maker is engulfed in a wave of criticism.

from WSJ.com: US Business http://ift.tt/1Tx8fgU
via IFTTT